Minilip EZ 40mg/10mg Tablet
Images are for reference. Actual packaging may vary.
Strip of 10 tablets • TabletPrescription requiredSchedule H
Minilip EZ 40mg/10mg Tablet
Atorvastatin (40mg) + Ezetimibe (10mg)
₹246.00
Strip of 10 tablets • Tablet
A valid prescription is required for this medicine.
1
Delivery
Safe & Secure
Easy Returns
24/7 Support
SMARTER CARE
A little guidance.
A better choice.
Haven’t found an alternative? A health advisor can help you understand what to do next.
No matching alternative found
We haven't found a cheaper matching alternative in our catalogue right now. Our health advisors can help you explore other options.
Active composition
Ezetimibe 10 mg
+1 more active ingredient
How It Works
Ezetimibe selectively inhibits the intestinal absorption of cholesterol and related phytosterols by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter.
Atorvastatin inhibits HMG-CoA reductase, decreasing cholesterol synthesis and promoting LDL receptor activity.
Medicine Strength
10 mg
All Active Ingredients
Ezetimibe10 mg
Atorvastatin40 mg
Uses & Benefits
Medical applications
PainHeadacheCholesterol
Minilip EZ 40mg/10mg Tablet is a fixed-dose combination product containing atorvastatin (40mg) and ezetimibe (10mg). It is indicated for the treatment of hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia. Atorvastatin, a statin, inhibits HMG-CoA reductase, an enzyme involved in cholesterol synthesis, thereby reducing low-density lipoprotein (LDL) cholesterol and triglycerides.
Read full descriptionShow less
Ezetimibe, a cholesterol absorption inhibitor, selectively inhibits the absorption of dietary cholesterol in the small intestine, thereby reducing LDL cholesterol. The combination of atorvastatin and ezetimibe has been shown to have a greater LDL cholesterol-lowering effect compared to monotherapy with either agent. Minilip EZ is contraindicated in patients with liver disease, pregnancy, or lactation.
It is also contraindicated in patients taking cyclosporine or strong CYP3A4 inhibitors. The most common adverse reactions include headache, pain, and muscle weakness. Minilip EZ should be used with caution in patients with renal impairment, as the ezetimibe component may accumulate in these patients. The recommended starting dose is 40mg/10mg daily, with the option to titrate to 80mg/20mg daily if needed.
Dosage & How to Use
How to use Minilip EZ Tablet Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Minilip EZ 40mg/10mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
Safety Advice
Important precautions
Side effects
Side-effect information is not available for this medicine. Please consult your doctor or pharmacist.
Safety Advice
Alcohol
It is unsafe to consume alcohol with Minilip EZ 40mg/10mg Tablet.
High Risk
Pregnancy
Minilip EZ 40mg/10mg Tablet is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Medical Advice
Driving
Minilip EZ 40mg/10mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Exercise Caution
Liver
Minilip EZ 40mg/10mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Minilip EZ 40mg/10mg Tablet may be needed. Please consult your doctor. Use of Minilip EZ 40mg/10mg Tablet is not recommended in patients with moderate to severe liver disease.
Regular Checkup
Breastfeeding
Minilip EZ 40mg/10mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Kidney
Minilip EZ 40mg/10mg Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Minilip EZ 40mg/10mg Tablet may be needed. Please consult your doctor.
Regular Checkup
Customer Reviews
0 reviews for Minilip EZ 40mg/10mg Tablet
